Pfizer Inc (PFE)

PFE on New York Consolidated

31.94USD
19 Dec 2014
Price Change (% chg)

$-0.03 (-0.09%)
Prev Close
$31.97
Open
$31.91
Day's High
$32.09
Day's Low
$31.61
Volume
44,949,818
Avg. Vol
26,159,971
52-wk High
$33.12
52-wk Low
$27.51

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.69
Market Cap (Mil.): $201,243.00
Shares Outstanding (Mil.): 6,300.66
Dividend: 0.28
Yield (%): 3.51

Financials

  PFE Industry Sector
P/E (TTM): 20.20 37.83 38.47
EPS (TTM): 1.58 -- --
ROI: 6.86 18.99 18.25
ROE: 13.42 19.75 19.13
Search Stocks

AstraZeneca CEO says new Pfizer bid unlikely: Swedish daily DI

STOCKHOLM - U.S. Pfizer is unlikely to come back with a fresh bid for AstraZeneca, the Anglo-Swedish pharmaceuticals group's top executive was quoted as saying by Swedish business daily Dagens Industri on Saturday.

20 Dec 2014

AstraZeneca CEO says new Pfizer bid unlikely-Swedish daily DI

STOCKHOLM, Dec 20 - U.S. Pfizer is unlikely to come back with a fresh bid for AstraZeneca, the Anglo-Swedish pharmaceuticals group's top executive was quoted as saying by Swedish business daily Dagens Industri on Saturday.

20 Dec 2014

Ex-Wyeth head Poussot to join Roche board, rather than Sanofi

PARIS - Former Wyeth chief executive Bernard Poussot looks to be out of the running to take over as the next boss of French drugmaker Sanofi, as Swiss rival Roche said on Friday he was joining its board.

12 Dec 2014

FDA warns Pfizer's antipsychotic could cause fatal skin reaction

- Pfizer Inc's antipsychotic Geodon and generic versions of the drug can trigger a potentially fatal skin reaction, the U.S. Food and Drug Administration warned on Thursday.

11 Dec 2014

FDA warns Pfizer's antipsychotic could cause fatal skin reaction

Dec 11 - Pfizer Inc's antipsychotic Geodon and generic versions of the drug can trigger a potentially fatal skin reaction, the U.S. Food and Drug Administration warned on Thursday.

11 Dec 2014

Pfizer bets on gene therapy as technology comes of age

LONDON - Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks.

08 Dec 2014

Pfizer bets on gene therapy as technology comes of age

LONDON, Dec 8 - Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks.

08 Dec 2014

WADA signs deal with Pfizer to share PED information

- The World Anti-Doping Agency (WADA) and Pfizer Inc signed an agreement on Wednesday that will see the U.S. drugmaker share information on products that could be used as performance-enhancing substances by athletes.

03 Dec 2014

UPDATE 1-Biogen plans late-stage Alzheimer's trial, shares rise

Dec 2 - Biogen Idec Inc's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque levels and significantly improved cognition in a small early-stage study.

02 Dec 2014

PRESS DIGEST - Sunday British business - Nov. 30

LONDON, Nov 30 - British newspapers reported the following business stories on Sunday. Reuters has not independently verified these media reports and does not vouch for their accuracy.

30 Nov 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $105.55 --
Novartis AG (NOVN.VX) CHF93.05 +0.95
Merck & Co., Inc. (MRK.N) $59.58 --
Roche Holding Ltd. (ROG.VX) CHF270.40 -18.30
Abbott Laboratories (ABT.N) $46.05 +0.28
Bayer AG (BAYGn.DE) €115.95 +1.95
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.60 +0.22
AstraZeneca plc (AZN.L) 4,565.00p -7.50
GlaxoSmithKline plc (GSK.L) 1,392.00p +13.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks